Cargando…

Quality assessment of selected co-trimoxazole suspension brands marketed in Nairobi County, Kenya

INTRODUCTION: Quality of medicines in both developed and developing countries is sometimes compromised due to infiltration of counterfeit, substandard or degraded medicines into the markets. It is a public health concern as poor quality medicines endanger public health where patients are exposed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Irungu, Beatrice Njeri, Koech, Lilian C., Ondicho, Joyce M., Keter, Lucia K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457504/
https://www.ncbi.nlm.nih.gov/pubmed/34551002
http://dx.doi.org/10.1371/journal.pone.0257625
_version_ 1784571112546369536
author Irungu, Beatrice Njeri
Koech, Lilian C.
Ondicho, Joyce M.
Keter, Lucia K.
author_facet Irungu, Beatrice Njeri
Koech, Lilian C.
Ondicho, Joyce M.
Keter, Lucia K.
author_sort Irungu, Beatrice Njeri
collection PubMed
description INTRODUCTION: Quality of medicines in both developed and developing countries is sometimes compromised due to infiltration of counterfeit, substandard or degraded medicines into the markets. It is a public health concern as poor quality medicines endanger public health where patients are exposed to chemical toxins and/or sub-therapeutic doses. This could lead to reduced treatment efficacy and promote development of drug resistance. Co-trimoxazole, a fixed dose combination of sulfamethoxazole and trimethoprim, is a broad spectrum for bacterial diseases and is also used as a prophylaxis for opportunistic infections in HIV infected individuals. This study evaluated quality of selected co-trimoxazole suspension brands marketed in Nairobi County, Kenya. METHODS: A total of 106 samples were collected, categorized into 15 brands and evaluated for active pharmaceutical ingredient content (API) and pH following United States Pharmacopeia. Assay for API was conducted using High Performance Liquid Chromatography. Results were compared with pharmacopeia references. Visual examination of labels and confirmation of retention status of the brands with Pharmacy and Poisons Board retention register was carried out. RESULTS: The samples were primarily of local origin (86.7%). On October 23, 2019, retention status of six of the fifteen brands documented were no longer listed in the Pharmacy and Poisons Board retention register. Of the 106 samples tested 70.6% and 86.8% were compliant with United States Pharmacopeia (USP) specifications for pH and API respectively while 84.0% adhered to packaging and labelling requirements. CONCLUSION: This study has demonstrated that majority of co-trimoxazole suspensions tested were compliant with USP requirements. Additionally, it has provided evidence of poor quality co-trimoxazole medicines that could compromise treatment of infectious diseases in children. This emphasizes the need for regular quality assurance tests to ensure only quality medicines are in the market.
format Online
Article
Text
id pubmed-8457504
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-84575042021-09-23 Quality assessment of selected co-trimoxazole suspension brands marketed in Nairobi County, Kenya Irungu, Beatrice Njeri Koech, Lilian C. Ondicho, Joyce M. Keter, Lucia K. PLoS One Research Article INTRODUCTION: Quality of medicines in both developed and developing countries is sometimes compromised due to infiltration of counterfeit, substandard or degraded medicines into the markets. It is a public health concern as poor quality medicines endanger public health where patients are exposed to chemical toxins and/or sub-therapeutic doses. This could lead to reduced treatment efficacy and promote development of drug resistance. Co-trimoxazole, a fixed dose combination of sulfamethoxazole and trimethoprim, is a broad spectrum for bacterial diseases and is also used as a prophylaxis for opportunistic infections in HIV infected individuals. This study evaluated quality of selected co-trimoxazole suspension brands marketed in Nairobi County, Kenya. METHODS: A total of 106 samples were collected, categorized into 15 brands and evaluated for active pharmaceutical ingredient content (API) and pH following United States Pharmacopeia. Assay for API was conducted using High Performance Liquid Chromatography. Results were compared with pharmacopeia references. Visual examination of labels and confirmation of retention status of the brands with Pharmacy and Poisons Board retention register was carried out. RESULTS: The samples were primarily of local origin (86.7%). On October 23, 2019, retention status of six of the fifteen brands documented were no longer listed in the Pharmacy and Poisons Board retention register. Of the 106 samples tested 70.6% and 86.8% were compliant with United States Pharmacopeia (USP) specifications for pH and API respectively while 84.0% adhered to packaging and labelling requirements. CONCLUSION: This study has demonstrated that majority of co-trimoxazole suspensions tested were compliant with USP requirements. Additionally, it has provided evidence of poor quality co-trimoxazole medicines that could compromise treatment of infectious diseases in children. This emphasizes the need for regular quality assurance tests to ensure only quality medicines are in the market. Public Library of Science 2021-09-22 /pmc/articles/PMC8457504/ /pubmed/34551002 http://dx.doi.org/10.1371/journal.pone.0257625 Text en © 2021 Irungu et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Irungu, Beatrice Njeri
Koech, Lilian C.
Ondicho, Joyce M.
Keter, Lucia K.
Quality assessment of selected co-trimoxazole suspension brands marketed in Nairobi County, Kenya
title Quality assessment of selected co-trimoxazole suspension brands marketed in Nairobi County, Kenya
title_full Quality assessment of selected co-trimoxazole suspension brands marketed in Nairobi County, Kenya
title_fullStr Quality assessment of selected co-trimoxazole suspension brands marketed in Nairobi County, Kenya
title_full_unstemmed Quality assessment of selected co-trimoxazole suspension brands marketed in Nairobi County, Kenya
title_short Quality assessment of selected co-trimoxazole suspension brands marketed in Nairobi County, Kenya
title_sort quality assessment of selected co-trimoxazole suspension brands marketed in nairobi county, kenya
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457504/
https://www.ncbi.nlm.nih.gov/pubmed/34551002
http://dx.doi.org/10.1371/journal.pone.0257625
work_keys_str_mv AT irungubeatricenjeri qualityassessmentofselectedcotrimoxazolesuspensionbrandsmarketedinnairobicountykenya
AT koechlilianc qualityassessmentofselectedcotrimoxazolesuspensionbrandsmarketedinnairobicountykenya
AT ondichojoycem qualityassessmentofselectedcotrimoxazolesuspensionbrandsmarketedinnairobicountykenya
AT keterluciak qualityassessmentofselectedcotrimoxazolesuspensionbrandsmarketedinnairobicountykenya